Skip to content

Author

C. Montoto

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-α as first- and second-line biologic treatment in Crohn's disease.

OBJECTIVE Much of the available real-world evidence on the gut-selective α4β7 integrin antibody vedolizumab comes from patients with repeated failure of anti-tumour necrosis factor-α (anti-TNFα) agents and other treatments. The EVOLVE-IBERIA study is aimed to generate additional real-world evidence for vedolizumab and...

J. F. Muñoz, Ana Gutiérrez Casbas, C. Rodríguez et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.